Physician profile
Lora J Pound
NPI 1154421709
$3,196.55
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $1,758 · 2021: $15.85 · 2022: $19.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $565.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $513.14 | 2019-2020 | |
| Novo Nordisk INC | $294.08 | 2019-2020 | |
| Amgen INC. | $288.92 | 2019-2020 | |
| Pfizer INC. | $265.51 | 2019-2020 | |
| Amarin Pharma, INC. | $255.26 | 2019-2020 | |
| Lilly USA, LLC | $204.03 | 2019-2020 | |
| Astellas Pharma US INC | $197.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $92.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.13 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $61.48 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.99 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $55.21 | 2019 | |
| Glaxosmithkline, LLC. | $40.18 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.36 | 2020-2022 | |
| Eisai INC. | $25.63 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $23.28 | 2020 | |
| Esperion Therapeutics, INC. | $21.44 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.78 | 2019 | |
| Mannkind Corporation | $12.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Pound listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.